Best Life Sciences Companies in Ohio, United States

Provider of a wearable drug delivery solution. The company's drug delivery device include enFuse for injectable therapies which enables a range of flexible delivery options for patients and healthcare providers, including a range of viscosities, volumes, delivery times, and sites for administration.

Funding rounds

• Dec 2025Series C$30M
• Jan 2022Series C$215M
• Sep 2020Conventional Debt$25M
• Oct 2018Series B$50M

Founders & team

Mike HoovenFounder & CEO

Investors

Oxford Finance, Sanofi, ORI Capital, CincyTech, Cincinnati Children’s, Cleveland Clinic

Tech stack

Animate.CssApache Http ServerApple Icloud MailBootstrapCloudflareCloudflare Bot Management

ClevelandDx has developed diagnostics technology to detect cancer in early-stage. The company uses specific biomarkers to distinguish the non-cancerous and cancerous conditions. The expression of these biomarkers is based on a proprietary technology that separates protein isoforms, based on structure.

Funding rounds

• Oct 2025Series E$14.4M
• Jan 2024Series E$75M
• Feb 2021Series D$19.4M
• Nov 2016Conventional Debt—

Founders & team

Arnon ChaitPresident And Ceo

Investors

LYFE Capital, Cleveland Clinic, Novo Holdings, Jumpstart, Merchavia Holdings and Investments, Serial Stage Venture Partners

Tech stack

AngularCloudflareCloudflare Bot ManagementCore-JsDocusignDropbox

Digital medical image management tool for providers. The company has developed software like MediView XR30, MediView XR50, and MediView XR90. It has features for augmented reality visualization, remote collaboration, clinical image analysis, and democratizing and informing healthcare delivery.

Funding rounds

• Nov 2025Series A$24M
• Oct 2025Series A$24M
• Dec 2024Series A$14M
• May 2023Series A$15M

Founders & team

Adam RakestrawCo-FounderMina FahimCEO

Investors

Mayo Clinic, GE Healthcare, JobsOhio, Inside View Investments, KKVS Syndicate, Cleveland Clinic

Tech stack

Apache Http ServerBackbone.JsCdnjsCloudflareCookieyesFont Awesome

Developer of cell therapies for the treatment of multiple diseases. The company uses HD-DoE technology platform to develop a pipeline for diabetes, cancer, bone marrow, Huntington's disease, and more.

Funding rounds

• Jan 2026Series B$20M
• May 2025Series B$20M
• Oct 2022Series A$10M
• Nov 2020Series A$6.6M

Founders & team

Jan JensenCo-Founder & CEO

Investors

Innovation Fund America, MAK Capital, BioEnterprise

Tech stack

Animate.CssAnime.JsCart FunctionalityCloudflareCloudflare Bot ManagementComplianz

Developer of non-implant peripheral nerve stimulation systems for pain management. This company provides a clinically proven, patient-preferred non-surgical option for managing chronic, intractable, post-surgical, post-traumatic, and post-operative pain. The system offers symptomatic relief and is indicated for up to 60 days of use. The most common adverse events are skin irritation and erythema. The company is focused on advancing non-opioid, non-surgical, minimally invasive pain management solutions.

Funding rounds

• Mar 2025Grant (prize money)$6M
• Feb 2024Convertible Debt$60M
• Jan 2024Series D$25.6M
• Oct 2021Series D$37M

Founders & team

Maria BennettFounder & CEO

Investors

Revelation Partners, RC Capital, Mutual Capital Partners, SLR, Defense.gov, Jumpstart Ventures

Tech stack

Apple Icloud MailCloudflareCloudflare Browser InsightsCookieyesCore-JsCrazy Egg

Enspire DBS Therapy is developing a therapy to recover patients from stroke. The company is using deep brain stimulation (DBS) to reprogram neurological input by stimulating the natural cerebral pathways within the brain. The company is conducting clinical trials to investigate the efficacy of DBS with physical therapy.

Funding rounds

• Jan 2026Series B$10.3M
• Aug 2023Series B$17.6M

Founders & team

Vince OwensCo-FounderScott KokonesCo-Founder & CEO

Investors

Cleveland Clinic, JobsOhio, Genesys Capital, JobsOhio Ventures, Guide Medical Ventures

AI-powered solutions transforming cardiothoracic diagnosis through advanced medical imaging software. The company is dedicated to revolutionizing radiology by providing tools for early and efficient detection of lung disease. Their ClearRead solutions leverage machine learning and advanced modeling to improve the accuracy and speed of disease detection in chest CT and XR images. The patented, FDA-cleared software is deployed in the clinic or the cloud, offering clinicians an unimpaired view for precise characterization and reporting of findings. The company's technology aims to streamline diagnostic processes, improve detection accuracy, and transform patient outcomes. They offer solutions for nodule detection, bone suppression, and workflow efficiency gains. The company's offerings are software agnostic and available via cloud or on-site options.

Developer of endovascular devices for the treatment of PAD and stenoses of AV fistulas and grafts. The company has developed, FLEX Scoring Catheter, a single-use, disposable device designed to facilitate the dilation of stenoses. It is indicated for use with PTA catheters to facilitate dilation of stenoses in the femoral and popliteal arteries and treatment of obstructive lesions.

Funding rounds

• Oct 2025Series C$49.2M
• Oct 2024Series B$7M
• Nov 2021Series B—
• Jun 2019Series B$1M

Founders & team

Denis HarringtonPresident & CEO

Investors

Endeavour Vision, RiverVest Venture Partners, S3 Ventures, Rocket Ventures, Global Cardiovascular Innovation Center

Tech stack

WordpressMysqlPhpBootstrapYoast SeoNginx

Developer of surgical navigation and image guidance system for endovascular procedures. The flagship product of the company is the Intra-Operative Positioning System (IOPS) based on 3D GPS-like surgical navigation technology for predictive modeling and clinical decision support. Also, it offers x-ray fluoroscopy for 2D image guidance.

Developing novel therapeutics for cardiopulmonary diseases, including PAH and COPD. The company is focused on creating humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies as a potential disease-modifying treatment. Their pioneering research highlights the pathogenic role of EMAP II in conditions like pulmonary arterial hypertension, chronic obstructive pulmonary disease, and viral-induced acute lung injury. The company leverages a network of preclinical and clinical scientists to advance its therapeutic pipeline. Their approach targets apoptosis, cell injury, endothelial cell function, and inflammation, aiming to provide innovative solutions for unmet medical needs in the cardiopulmonary space. The company is focused on research and development of novel treatments.

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds. Due to the results achieved over the last three years of testing in areas such as Stem Cells, Inflammation, Oxidation Stress and Diabetes treatment, the company is now preparing a submission to enter into phase I and II in human clinical trials.

Developer of therapeutics and diagnostics for oncology patients. The company has developed Entadfi an oral therapeutic for the treatment of benign prostatic hyperplasia a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Funding rounds

• Sep 2025Post IPO$13M
• Oct 2024Post IPO$2M
• Jul 2019Seed$7M

Founders & team

Joseph HernandezFounder & CEONeil CampbellCEO

Investors

CincyTech

Tech stack

AccessibeDiviFlywheelGoogle Font ApiJqueryJquery Migrate